In melanoma patients, when compared with the real-time PCR (RT-PCR) approach cobas® 4800 BRAF V600 mutation test (Roche, Basel, Switzerland), the Sanger sequencing achieved an overall agreement ranging from 95.2% to 97.7% [49,50]. Here, BRAF is linked to melanoma.